Your All-In AAV, All-The-Time CDMO

Gene therapy programs face unique challenges in achieving speed, scalability, and regulatory compliance. AAV-based manufacturing requires precision and efficiency to meet clinical and commercial demands while minimizing risk and controlling costs. Advanced technology platforms now enable developers to reach cGMP readiness in as little as six months, significantly accelerating timelines without sacrificing quality.

This approach combines deep scientific expertise with robust CMC capabilities, ensuring confidence at every stage of development. Large-scale capacity dedicated exclusively to AAV production supports both early-phase and commercial programs, while flexible solutions help innovators adapt to evolving requirements. Beyond operational excellence, initiatives that reserve production slots for nonprofit organizations expand access to life-changing therapies for rare and pathway diseases. With a proven track record of successful regulatory submissions, thousands of AAV batches, and experience across numerous serotypes, this model empowers developers to move from concept to clinic with certainty and speed. Delve into how streamlined manufacturing strategies can help deliver groundbreaking treatments to patients worldwide—faster, safer, and at scale.